The analysis addresses differences in regional access times for drug reimbursement in Italy.
Following the official publication for drug reimbursement in the Gazzetta Ufficiale, the process includes phases such as inclusion in the Regional Hospital Therapeutic Handbook (PTOR), identification of authorised prescription centres, and competitive bidding. Based on an Excel database of 184 procedures from December 11, 2019, to September 16, 2022, the research
reveals variations in access times among regions.
Key results include an overall average regional access time of 65.65 days, with extension indications having a shorter average access time (67 days) compared to new active substances (112 days). Access times increase for rare diseases (99 days) compared to non-rare diseases (95 days) for new active substances. Additionally, access times decrease for innovative substances (68
days) compared to non-innovative ones (144 days). The study aims to highlight factors influencing disparities in regional access and suggests the need to streamline processes for fair and timely patient access to medications.
The analysis addresses differences in regional access times for reimbursement of drugs in Italy.
The publication in the Official Journal for the reimbursement of a drug is followed by the stages of inclusion in the Regional Hospital Therapeutic Record (PTOR), identification of authorised prescription centres and tenders. The research, based on an Excel database of 184 procedures from 11/12/2019 to 16/09/2022, reveals variations in access times between regions. Key results
include an overall regional average access time of 65.65 days, with indication extensions having a shorter average access time (67 days) than new active substances (112 days). Access times increase for rare diseases (99 days) compared to non-rare diseases (95 days) for new active substances. In addition, access times
decrease for innovative substances (68 days) compared to non-innovative ones (144 days). The study aims to highlight factors influencing disparities in regional access and suggests the need to simplify processes for fair and timely patient access to medicines.
